Team creates neutralising antibody, effective not only against all genetically divergent global HIV-1 strains, but also on latent cells.
08 May 2018 1:28 PM
However, rival ViiV Healthcare, quickly filed a lawsuit alleging that Gilead was infringing patents on ViiV’s dolutegravir.
08 Feb 2018 9:54 AM